AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: Preclinical activity in HER2 non-amplified inflammatory breast cancer models

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Mu, Zhaomei ^a,b   Klinowska, Teresa ^c   Dong, Xiaoshen ^d   Foster, Emily ^c   Womack, Chris ^c   Fernandez, Sandra V ^a,b   Cristofanilli, Massimo ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

^d CHINA MEDICAL UNIVERSITY   (China)

Author keywords

AZD8931; EGFR; HER2; HER3; Inflammatory breast cancer; Paclitaxel

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE AMPLIFICATION; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MICE; MICE, SCID; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903560408     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-47     Document Type: Article

References (31)

1. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH, J Natl Cancer Inst 2005 97 13 966 975 10.1093/jnci/dji172 15998949 (Pubitemid 41430562)
2. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M, Ann Oncol 2011 22 3 515 523 10.1093/annonc/mdq345 20603440
3. Inflammatory breast cancer: a review. Jaiyesimi IA, Buzdar AU, Hortobagyi G, J Clin Oncol 1992 10 6 1014 1024 1588366
4. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN, Cancer 2007 110 7 1436 1444 10.1002/cncr.22927 17694554 (Pubitemid 47463056)
5. Inflammatory breast cancer: the disease, the biology, the treatment. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Cristofanilli M, CA Cancer J Clin 2010 60 6 352 375
6. Inflammatory breast cancer: what progress have we made? Dawood S, Cristofanilli M, Oncology 2011 25 3 264 270 21548470
7. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M, Ann Oncol 2007 18 6 1021 1029 10.1093/annonc/mdm060 17351259 (Pubitemid 47050493)
8. Role of epidermal growth factor receptor in breast cancer. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT, Breast Cancer Res Treat 2012 136 2 doi:10.1007/s10549-012-2289-9
9. Molecular targets for treatment of inflammatory breast cancer. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT, Nat Rev Clin Oncol 2009 6 7 387 394 10.1038/nrclinonc.2009.73 19468291
10. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY, Breast Cancer Res Treat 2006 95 3 243 255 10.1007/s10549-005-9015- 9 16261404
11. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H, Breast Cancer Res 2009 11 1 9 doi:10.1186/bcr2225 10.1186/bcr2225 19228416
12. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL, Lancet 1987 1 8547 1398 1402 2884496 (Pubitemid 17078859)
13. Epidermal growth factor-related peptides and their receptors in human malignancies. Salomon DS, Brandt R, Ciardiello F, Normanno N, Crit Rev Oncol Hematol 1995 19 3 183 232 10.1016/1040-8428(94)00144-I 7612182
14. Inflammatory breast cancer (IBC): clues for targeted therapies. Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M, Breast Cancer Res Treat 2013 140 1 23 33 10.1007/s10549-013- 2600-4 23784380
15. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M, J Exp Clin Cancer Res 2013 32 70 doi:10.1186/1756-9966-32-70
16. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB3 receptor blockade in cancer. Hickinson M, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D, Clin Cancer Res 2010 16 4 1159 1169 10.1158/1078-0432.CCR-09-2353 20145185
17. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Burness ML, Grushko TA, Olopade OI, Cancer J 2010 16 1 23 32 10.1097/PPO.0b013e3181d24fc1 20164687
18. Prognostic markers in triple-negative breast cancer. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO, Cancer 2007 109 1 25 32 10.1002/cncr.22381 17146782 (Pubitemid 46120191)
19. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G, Int J Cancer 1989 43 2 201 208 10.1002/ijc.2910430205 2563719 (Pubitemid 19062410)
20. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA, Oncologist 2011 16 12 1675 1683 10.1634/theoncologist.2011-0196 22147002
21. Role of epidermal growth factor receptor in breast cancer. Masuda H, Zhang DW, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT, Breast Cancer Res Treat 2012 136 2 331 345 10.1007/s10549-012-2289-9 23073759
22. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Eccles SA, Int J Dev Biol 2011 55 7-9 685 696 22161825
23. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL, J Clin Oncol 2008 26 7 1066 1072 10.1200/JCO.2007.13.9949 18212337
24. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT, Mol Cancer Ther 2008 7 7 1846 1850 10.1158/1535-7163.MCT-08-0168 18644997
25. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N, J Clin Oncol 2010 28 20 3248 3255 10.1200/JCO.2009.21.8594 20530274
26. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, Haley JD, Mol Cancer Ther 2007 6 2 532 541 10.1158/1535-7163.MCT-06- 0462 17308052 (Pubitemid 46332455)
27. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast. Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A, J Clin Oncol 2013 31 20 2586 2592 10.1200/JCO.2012.46.2408 23733761
28. Panitumumab in combination with FEC100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple negative breast cancer (TNBC): preliminary results of a multicenter neoadjuvant pilot phase II study. Nabholtz J, Weber B, Mouret-Reynier M, Gligorov J, Coudert BP, Vanlemmens L, Petit T, Tredan O, Van Praagh-Doreau I, Dubray-Longeras P, Ferriere J, Nayl B, Tubiana-Mathieu N, Jouannaud C, Devaud H, Abrial C, Planchat E, Chalabi N, Penault-Llorca FM, Cholletet PJM, J Clin Oncol 2011 29 suppl 11574
29. Trends for inflammatory breast cancer: is survival improving? Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobágyi GN, Oncologist 2007 12 8 904 912 10.1634/theoncologist.12-8-904 17766649 (Pubitemid 47359132)
30. Approach to inflammatory breast cancer. Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M, Can Fam Phys 2009 55 1 25 31
31. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT, Clin Cancer Res 2009 15 21 6639 6648 10.1158/1078-0432.CCR-09-0951 19825949